Atazanavir found to help improve lipid profile. IDSA study offers good news for HIV care.
A new protease inhibitor called atazanavir actually was found to improve the lipid profile of HIV patients in a 48-week study. The study compared the total cholesterol from baseline and at 48 weeks following treatment with atazanavir.
D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*
D017320:HIV Protease Inhibitors